A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can vary from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening for good reason.”
The pregnancy vaccine functions by activating the mother’s body’s defences to produce protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity offers newborns with immediate protection from the moment of birth, exactly when they are highly susceptible to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a two-week gap is sufficient to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85% coverage when vaccinated four weeks before birth
- Antibodies from the mother transferred through the placenta protect newborns from day one
- Protection possible with two-week gap before early delivery
- Vaccination in the third trimester still provides significant protection for infants
Strong evidence from recent research
The effectiveness of the RSV vaccine administered during pregnancy has been established through a extensive research programme carried out throughout England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90% of all births during that six-month period, providing strong and reliable information of the vaccine’s actual performance. The study’s conclusions have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scope of this study provides healthcare professionals and parents-to-be with trust in the vaccine’s proven efficacy across diverse populations and circumstances.
The results present a striking picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This clear distinction underscores the vaccine’s essential role in preventing serious illness in newborns. The decrease in hospital admissions surpassing 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms connected with severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.
Methodology and scope of study
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The large sample size and thorough nature of the data collection ensured that findings were statistically significant and indicative of the general population, rather than individual cases or limited subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology assessed actual clinical results rather than controlled laboratory conditions, providing real-world data of how the vaccine functions when administered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the risks
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require intensive hospital care for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection causes inflammation deep within the lungs and airways, making it perilously hard for vulnerable newborns to feed and breathe effectively. Parents commonly see their babies fighting for breath, their chests heaving as they attempt to draw sufficient oxygen into their weakened respiratory system. Whilst most infants recover with supportive care, a limited though important number die from respiratory syncytial virus complications each year, making vaccination as prevention a vital health service imperative for defending the most vulnerable and youngest members of society.
- RSV causes lung inflammation, causing serious respiratory problems in infants
- Half of all infants catch the virus in their first few months of life
- Symptoms vary between mild colds to life-threatening chest infections needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV each year
- Few babies die from RSV related complications annually in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have stressed the value of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing is crucial for ensuring newborns receive the maximum immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery delivers approximately 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy forward to increase the antibodies transferred to their babies through the placenta.
The guidance from public health bodies stays clear: pregnant women should make a priority of vaccination during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for vulnerable newborns during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.
Regional disparities in vaccination
Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have differed across different regions and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to increase awareness and availability of the jab. These regional differences reflect variations in medical facilities, engagement approaches, and local engagement efforts, though the overall statistics shows robust and reliable protection regardless of geographical location.
- NHS trusts launching multiple messaging strategies to engage with women during pregnancy
- Inconsistencies across regions in immunisation take-up in different parts of England necessitate strategic intervention
- Local healthcare systems adapting programmes to meet community needs and circumstances
Practical implications and parent viewpoints
The vaccine’s outstanding effectiveness delivers concrete gains for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV before the rollout of this safeguarding intervention, the 80% decrease in admissions represents thousands of infants protected against critical disease. Parents no longer face the upsetting situation of seeing their babies struggle for breath or labour to feed, symptoms that characterise serious RSV disease. The vaccine has markedly changed the terrain of neonatal respiratory health, offering expectant mothers a active means to safeguard their most at-risk babies during those vital initial period.
For families like that of Malachi, whose severe RSV infection caused devastating brain damage, the vaccine’s availability carries significant emotional significance. His mother’s advocacy for the jab highlights the profound consequences that vaccine-preventable disease can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to expectant mothers navigating their final trimester, converting what was once an inevitable seasonal threat into a manageable risk.